Credit Suisse Questions Financials of Rumored Danone, Mead Johnson (MJN) Deal
Get Alerts MJN Hot Sheet
Rating Summary:
3 Buy, 15 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Mead Johnson (NYSE: MJN) gained last week after Reuters reported Danone is preparing to make an offer, but in the view of Credit Suisse analyst Alex Molloy, financials of a potential transaction "hard to fathom."
"It's not that we question the strategic logic. Infant Milk Formula is one of the most attractive consumer staple markets, strongly branded with good growth - even if Danone has had some unfortunate mishaps of late," said Molloy. "But quite how the financial case adds up is hard to fathom."
"If we assume a multiple consistent with recent similar transactions (and a 30% premium to MJN's closing price), we estimate the starting return on investment would be under 3½%. Even assuming savings of 7% of MJN sales (consistent with Nestlé/Wyeth) it would still take a decade for returns to beat an 8% cost of capital. And how might the group finance this? Selling Clinical (for€5bn?) and buying MJN for cash would see net debt to EBITDA at 5x – too high. So we believe another equity issue would be necessary, testing the patience of shareholders. Perhaps a strategic shareholder/partner is waiting in the wings to support such a move? A Sovereign Wealth Fund?" he continued.
"If we assume a target net debt / EBITDA of 3.5x then some €7bn of equity would be needed to fund this, diluting EPS by 7-10% pro forma, or just about neutral if the 7% savings as above can be delivered. On balance, we believe Danone will have a hard job convincing investors that such a move makes sense financially. The group's history of putting strategic ambition above financial logic looks set to be tested again," he added.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker In Talks With Four Automakers For Possible Sale - Insider
- Mangoceuticals (MGRX) Acquires Global Preventive Care Patent Portfolio
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Mergers and Acquisitions, RumorsRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!